{"nctId":"NCT00040742","briefTitle":"Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer","startDateStruct":{"date":"2003-03"},"conditions":["Nausea","Vomiting"],"count":745,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]},{"label":"0.5g ginger","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: ginger","Other: placebo"]},{"label":"1.0g ginger","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: ginger","Other: placebo"]},{"label":"1.5g ginger","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: ginger"]}],"interventions":[{"name":"ginger","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of cancer and be scheduled to receive at least 3 courses of chemotherapy\n\n  * Scheduled to receive chemotherapy with no planned interruption by radiotherapy or surgery\n  * Chemotherapy courses must be separated by at least 2 weeks from day 1 to day 1 of next course\n* Must have experienced nausea of any degree of severity after completion of the first study-related course of chemotherapy\n* Received a prior 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) with dexamethasone (DM) given at any dose and by any route (or equivalent dose of IV methylprednisolone (MePRDL)) on day 1 of course 1 of chemotherapy\n* Scheduled to receive a 5-HT3 receptor antagonist antiemetic with DM (or equivalent dose of IV MePRDL) on day 1 of courses 2 and 3 of chemotherapy\n* No symptomatic brain metastases\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Platelet count greater than 100,000/mm\\^3 at second course of chemotherapy\n* No prior bleeding or blood coagulation disorder (e.g., thrombocytopenia or platelet dysfunction)\n\nHepatic:\n\n* No prior coagulation factor deficiency\n\nRenal:\n\n* Not specified\n\nCardiovascular:\n\n* No prior vascular defect\n\nOther:\n\n* Able to understand English\n* No concurrent or impending bowel obstruction\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No concurrent interferon therapy\n\nChemotherapy:\n\n* See Disease Characteristics\n* At least 6 months since other prior chemotherapy\n\nEndocrine therapy:\n\n* Not specified\n\nRadiotherapy:\n\n* See Disease Characteristics\n* No concurrent radiotherapy\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* No concurrent warfarin or heparin for therapeutic anticoagulation\n* Concurrent low-dose warfarin for maintenance of venous access allowed\n* Concurrent rescue medications for control of symptoms caused by the cancer or its treatment allowed as clinically indicated","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline of Peak Acute Nausea","description":"Nausea evaluated on a 7-point semantic rating scale anchored by \"1\" = \"Not at all nauseated\" and by \"7\" = \"Extremely nauseated.\" Acute nausea calculated as the maximum of the Day 1 Evening and Night nausea ratings.\n\nChange from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of peak acute nausea used as the outcome measure.\n\nNegative values for this outcome are favorable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.85"},{"groupId":"OG001","value":"-0.56","spread":"1.83"},{"groupId":"OG002","value":"-0.44","spread":"1.79"},{"groupId":"OG003","value":"-0.15","spread":"1.82"}]}]}]},{"type":"SECONDARY","title":"Average Nausea Severity","description":"Nausea evaluated on a 7-point semantic rating scale anchored by \"1\" = \"Not at all nauseated\" and by \"7\" = \"Extremely nauseated.\" Acute nausea calculated as the average of the Day 1 Evening and Night nausea ratings.\n\nChange from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of average acute nausea used as the outcome measure.\n\nNegative values for this outcome are favorable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.58"},{"groupId":"OG001","value":"-0.44","spread":"1.67"},{"groupId":"OG002","value":"-0.34","spread":"1.64"},{"groupId":"OG003","value":"-0.05","spread":"1.68"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":188},"commonTop":["Gastrointestinal symptoms","Bruising/flushing, rash","Bleeding","Blood disorders","Infection"]}}}